Research programme: inflammatory disease therapeutics - F-star/Merck Serono
Latest Information Update: 04 Feb 2014
At a glance
- Originator f-star; Merck Serono
- Class Antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Inflammation
Most Recent Events
- 04 Feb 2014 Early research is ongoing in Europe
- 07 Sep 2011 Early research in Inflammation in Europe (Parenteral)